Introducing AGED Diagnostics
Active Genomes Expressed
Welcome. We’re AGED Diagnostics, and we’re disrupting the hepatology industry using genomic innovation! Our technology has been recognized by market leaders and our scalable business model is setting the trend for industry standards. Curious to find out more? Browse through our website, and get in touch if you would like to request a demo.
Hepatologists (who diagnose and treat disease of the liver) can identify patients high risk for developing liver cancer, but the invasiveness and cost of current diagnostic tests lead many patients to drop out of monitoring programs. AGED’s product will provide physicians a method to keep patients in the monitoring program for early detection, intervention and improved outcomes for patients and their families.
UNMET MEDICAL NEEDS
Hepatocellular Carcinoma (HCC or liver cancer) is the fastest growing cancer both worldwide and in the US. The current blood tests for HCC are less than 60% accurate and often fail to detect tumors at an early stage, and more accurate imaging alternatives are expensive.
These challenges mean most patients are diagnosed at late stages, at which time patient outcomes are poor and mortality rates are high and healthcare spending can cost up to $1,000,000 per patient. AGED is addressing these pain points by developing a diagnostic tool with a keen focus on early detection.
WHAT WE DO
AGED Diagnostics is developing the most accurate blood test for liver cancer to help hepatologists improve patient outcomes and reduce the financial burden on health insurers. AGED’s solution will be more cost-effective than other approaches, and be able to diagnose liver cancer earlier than other methods at a time when treatment is most effective.
AGED technology targets multiple clinically relevant markers to increase sensitivity and specificity. Liver cancer has a handful of underlying causes, while current biomarkers do not capture these differences, AGED is building our design using the intricacies necessary to capture differences between patient populations.
Meet The Team
AGED Core Team
Founder & CEO
Managing Scientific Director
Zayas R. Sison III A, Buetow K, Roberts LR, Kuhnsman A, Nagalo BM. Transcriptional Landscape of Hepatocellular Carcinoma Reveals that Patient Ethnic-Origin Influences Patterns of Expression.
Arora M, Bogenberger JM, Abdelrahman A, Leiting JL, Chen X, Egan JB, Kasimsetty A, Lenkiewicz E, Malasi S, Uson PLS, Nagalo BM, Zhou Y, Salomao MA, Kosiorek HE, Braggio E, Barrett MT, Truty MJ, Borad MJ. Evaluation of NUC-1031: a first-in-class ProTide in biliary tract cancer. Cancer Chemother Pharmacol. 2020 Jun;85(6):1063-1078. doi: 10.1007/s00280-020-04079-z. Epub 2020 May 21. PMID: 32440762.
Nagalo BM, Breton CA, Zhou Y, Arora M, Bogenberger JM, Barro O, Steele MB, Jenks NJ, Baker AT, Duda DG, Roberts LR, Russell SJ, Peng KW, Borad MJ. Oncolytic Virus with Attributes of Vesicular Stomatitis Virus and Measles Virus in Hepatobiliary and Pancreatic Cancers. Mol Ther Oncolytics. 2020 Sep 25;18:546-555. doi: 10.1016/j.omto.2020.08.007. Epub 2020 Aug 19. PMID: 32839735; PMCID: PMC7437509.
Eko Mba JM, Bisseye C, Ntsame Ndong JM, Mombo LE, Bengone C, Mouelet Migolet G, M'batchi B, Kosiorek HE, Butterfield RJ, Roberts LR, Borad MJ, Nagalo BM. Prevalent hepatitis B surface antigen among first-time blood donors in Gabon. PLoS One. 2018 Apr 13;13(4):e0194285. doi: 10.1371/journal.pone.0194285. PMID: 29652917; PMCID: PMC5898709.
Wongjarupong N, Yonli AT, Nagalo BM, Djigma FW, Somda SK, Hassan MA, Mohamed EA, Sorgho AP, Compaore TR, Soubeiga ST, Kiendrebeogo I, Sanou M, Diarra B, Yang HI, Chen CJ, Ouattara AK, Zohoncon TM, Martinson JJ, Buetow K, Chamcheu JC, Antwi SO, Borad MJ, Simpore J, Roberts LR. Characteristics of Patients With Chronic Hepatitis B Virus Infection With Genotype E Predominance in Burkina Faso. Hepatol Commun. 2020 Sep 15;4(12):1781-1792. doi: 10.1002/hep4.1595. PMID: 33305149; PMCID: PMC7706297.
Sorgho PA, Martinson JJ, Djigma FW, Yonli AT, Nagalo BM, Compaore TR, Obiri-Yeboah D, Diarra B, Sombie HK, Zongo AW, Ouattara AK, Soubeiga STR, Traore L, Roberts LR, Simpore J. Insights into the Interplay between KIR Gene Frequencies and Chronic HBV Infection in Burkina Faso. Mediterr J Hematol Infect Dis. 2018 Nov 1;10(1):e2018060. doi: 10.4084/MJHID.2018.060. PMID: 30416692; PMCID: PMC6223576.
Diarra B, Yonli AT, Sorgho PA, Compaore TR, Ouattara AK, Zongo WA, Tao I, Traore L, Soubeiga ST, Djigma FW, Obiri-Yeboah D, Nagalo BM, Pietra V, Sanogo R, Simpore J. Occult Hepatitis B Virus Infection and Associated Genotypes among HBsAg-negative Subjects in Burkina Faso. Mediterr J Hematol Infect Dis. 2018 Jan 1;10(1):e2018007. doi: 10.4084/MJHID.2018.007. PMID: 29326804; PMCID: PMC5760064.
Eko Mba JM, Bisseye C, Mombo LE, Ntsame Ndong JM, Mbina Ekayeng SC, Bengone C, M'batchi B, Nagalo BM. Assessment of rapid diagnostic tests and fourth-generation Enzyme-Linked Immunosorbent Assays in the screening of Human Immunodeficiency and Hepatitis B virus infections among first-time blood donors in Libreville (Gabon). J Clin Lab Anal. 2019 Mar;33(3):e22824. doi: 10.1002/jcla.22824. Epub 2018 Nov 28. PMID: 30485543; PMCID: PMC6818564.
Simpore A, Bisseye C, Nagalo BM, Sanou M, Nébié Y, Ghoma-Linguissi LS, Dahourou H, Sawadogo B, Djigma F, Ouattara S, Pietra V, Nichol J, Simpore J. Importance of extending the use of polymerase chain reaction in the diagnosis of venereal syphilis in a blood transfusion center in Burkina Faso, West Africa. Pan Afr Med J. 2014 May 15;18:56. doi: 10.11604/pamj.2014.18.56.3850. PMID: 26113890; PMCID: PMC4473781.
Zeba MT, Sanou M, Bisseye C, Kiba A, Nagalo BM, Djigma FW, Compaoré TR, Nebié YK, Kienou K, Sagna T, Pietra V, Moret R, Simporé J. Characterisation of hepatitis C virus genotype among blood donors at the regional blood transfusion centre of Ouagadougou, Burkina Faso. Blood Transfus. 2014 Jan;12 Suppl 1(Suppl 1):s54-7. doi: 10.2450/2013.0089-12. PMID: 24599906; PMCID: PMC3934227.
Tao I, Bisseye C, Nagalo BM, Sanou M, Kiba A, Surat G, Compaoré TR, Traoré L, Nikiema JB, Pietra V, Zongo JD, Simpore J. Screening of Hepatitis G and Epstein-Barr Viruses Among Voluntary non Remunerated Blood Donors (VNRBD) in Burkina Faso, West Africa. Mediterr J Hematol Infect Dis. 2013 Sep 2;5(1):e2013053. doi: 10.4084/MJHID.2013.053. PMID: 24106603; PMCID: PMC3787664.
Nagalo BM, Bisseye C, Sanou M, Kienou K, Nebié YK, Kiba A, Dahourou H, Ouattara S, Nikiema JB, Moret R, Zongo JD, Simpore J. Seroprevalence and incidence of transfusion-transmitted infectious diseases among blood donors from regional blood transfusion centres in Burkina Faso, West Africa. Trop Med Int Health. 2012 Feb;17(2):247-53. doi: 10.1111/j.1365-3156.2011.02902.x. Epub 2011 Oct 12. PMID: 21988100.
Sombié HK, Sorgho AP, Kologo JK, Ouattara AK, Yaméogo S, Yonli AT, Djigma FW, Tchelougou D, Somda D, Kiendrébéogo IT, Bado P, Nagalo BM, Nagabila Y, Adoko ETHD, Zabsonré P, Millogo H, Simporé J. Glutathione S-transferase M1 and T1 genes deletion polymorphisms and risk of developing essential hypertension: a case-control study in Burkina Faso population (West Africa). BMC Med Genet. 2020 Mar 19;21(1):55. doi: 10.1186/s12881-020-0990-9. PMID: 32188413; PMCID: PMC7081581.
Get in Touch
3400 Prospect St, Washington DC 20007